新闻
CRL
--
0.00%
--
Most likely large-cap and small-cap merger candidates -BofA
BofA Securities screened for stocks with the the characteristics most likely to attract suitors, both in the large- and small-cap universes. For S&P 500 (SP500) (SPY) targets, BofA: Screens based
Seekingalpha · 17小时前
Charles River (CRL) DSA Arm Prospers, Currency Headwind Stays
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Zacks · 5天前
--UBS Adjusts Charles River Laboratories International Price Target to $378 From $420, Maintains Buy Rating
MT Newswires · 05/05 12:39
--Morgan Stanley Adjusts Charles River Laboratories International's Price Target to $350 from $430, Keeps Overweight Rating
MT Newswires · 05/05 12:21
Research Alert: CFRA Lifts View On Shares Of Charles River Laboratories To Buy From Hold
MT Newswires · 05/05 11:07
--KeyBanc Adjusts Price Target on Charles River Laboratories International to $300 From $390, Keeps Overweight Rating
MT Newswires · 05/05 07:35
Charles River (CRL) Q1 Earnings Top, Gross Margin Falls
Charles River (CRL) Q1 results highlight 9.8% organic revenue growth, driven by strength across all three segments.
Zacks · 05/04 15:42
Charles River: Q1 Earnings Insights
  Charles River (NYSE:CRL) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/04 12:21
Charles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates
Charles River (CRL) delivered earnings and revenue surprises of 1.48% and 0.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 12:15
Charles River Laboratories Non-GAAP EPS of $2.75 beats by $0.03, revenue of $913.9M beats by $5.26M; updates FY22 guidance
Charles River Laboratories press release (NYSE:CRL): Q1 Non-GAAP EPS of $2.75 beats by $0.03. Revenue of $913.9M (+10.8% Y/Y) beats by $5.26M. The Company is updating its 2022 financial guidance,
Seekingalpha · 05/04 11:05
Charles River Q1 EPS $2.75 Beats $2.71 Estimate, Sales $913.90M Beat $910.10M Estimate
Charles River (NYSE:CRL) reported quarterly earnings of $2.75 per share which beat the analyst consensus estimate of $2.71 by 1.48 percent. This is a 8.7 percent increase over earnings of $2.53 per share from the same
Benzinga · 05/04 11:02
Charles River Laboratories International Q1 Non-GAAP EPS, Revenue Increase; Raises 2022 Revenue Growth Guidance
MT Newswires · 05/04 08:15
-- Earnings Flash (CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Reports Q1 EPS $2.75, vs. Street Est of $2.72
MT Newswires · 05/04 07:22
Notable earnings before Wednesday's open
ABC, AMRN, AMRX, ASC, ATI, AVA, AVNS, BDC, BIP, BLX, BRKR, BRY, BWA, CDW, CFMS, CGAU, CLDT, CLH, CLVS, CMLS, CRL, CRTO, CSII, CVS, DCPH, DIN, DOC, OTCPK:EADSF, EAT, EDIT,
Seekingalpha · 05/03 15:43
MedTech Stocks' Q1 Earnings Due on May 4: CRL, IDXX & NUVA
MedTech companies' results are likely to reflect a rebound in the base business. Let's see how CRL, IDXX and NUVA fare this time.
Zacks · 05/03 14:34
Preview: Charles River's Earnings
Charles River (NYSE:CRL) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Charles River will report an earnings per share (EPS) of $2.71.
Benzinga · 05/03 14:11
Charles River Laboratories International's (NYSE:CRL) five-year total shareholder returns outpace the underlying earnings growth
Charles River Laboratories International, Inc. ( NYSE:CRL ) shareholders might be concerned after seeing the share...
Simply Wall St. · 04/28 11:09
Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 04/27 19:03
Charles River (CRL) to Report Q1 Earnings: What's in Store?
Robust global demand for the research model and multiple initiatives to expedite the discovery process are likely to have contributed to Charles River's (CRL) first-quarter results.
Zacks · 04/27 14:24
Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets
WILMINGTON, Mass. & BOSTON, April 27, 2022--Charles River and Valo have launched Logica, an AI-powered drug solution that translates biological insights into optimized preclinical assets.
Business Wire · 04/27 12:00
微牛提供丰富的实时CRL股票新闻,让你可以通过多个平台了解CRL股票行情最新动态,这些免费的查尔斯河实验室新闻可以帮助你做出明智投资。
CRL 简况
Charles River Laboratories International, Inc.是一家提供全方位服务的早期合同研究公司。该公司为帮助制药和生物技术公司、政府机构和学术机构进行研究和药物开发而提供产品和服务。该公司通过两个部门运营:探索及安全评估部门和制造解决方案(制造)部门。探索及安全评估部门包括通过早期开发过程获取药物所需的服务,包括探索服务(一种非监管服务,可帮助客户识别、筛选和选择用于药物开发的先导化合物)以及受监管和不受监管的(良好实验室规范(GLP)和非GLP)安全评估服务。制造部门包括微生物解决方案、生物制剂解决方案和禽疫苗服务。